New synergic biomaterials for anti-cancer therapy
- Authors: Swanepoel, Bresler
- Date: 2019
- Subjects: Pharmaceutical chemistry , Cancer -- Research , Biomedical materials
- Language: English
- Type: Thesis , Masters , MSc
- Identifier: http://hdl.handle.net/10948/43957 , vital:37087
- Description: In the last two decades, anti-cancer therapy has grown considerably with the help of both natural and synthetic anti-cancer compounds but, the search for new and improved cancer treatment remains an ongoing and important issue. Some anti-cancer compounds such as cisplatin are limited by their toxicity in normal tissues and the development of drug resistance. Therefore, in order to address drug resistance and side-effects of anti-cancer agents, recent research has been focusing on finding novel combinations of anti-cancer agents that have non-overlapping mechanisms of action. The first objective of this study was to determine the mechanism of action of Anemone nemorosa, Artemisia afra, N-[[3-(4-bromophenyl)-1H-pyrazol-5-yl]-carbamothioyl]-4-chloro-benzamide (BC-7) and N-benzoyl-N’-(3-(4-bromophenyl)-1H-pyrazol-5-yl)-thiourea (BT-7) through cell cycle arrest, phosphatidylserine translocation (PS), caspase activation and mitochondrial membrane depolarization. This study has shown that A. nemorosa, BC-7 and A. afra are capable of inducing cell death within three cancer cell lines namely HeLa, MeWo and HepG2, at varying degrees. HeLa cells were the most susceptible to treatment with A. nemorosa and BC-7 with IC50 values of 20.33 ± 2.480 μg/ml and 65.58 ± 8.400 μM (28.58 ± 3.660 μg/ml), respectively. A. afra was the most active against HepG2 cells with an IC50 value of 37.55 μg/ml. BT-7 was not cytotoxic against any of the cancer cell lines. The effects on HeLa cells and their progression through the cell cycle indicated that cells were arrested in the early M phase for all treatments. The induction of apoptosis was confirmed by an increase in PS translocation and activation of caspase 3 and 8 as well as a decrease in the mitochondrial membrane potential. It was deduced that A. nemorosa, A. afra and BC-7 induce caspase-dependent apoptosis in a mitochondrial dependent manner. The second objective of this study was to investigate the potential of A. nemorosa, A. afra and BC-7 to target various mediators involved in the inflammatory response as an alternative method in which cell death may be induced. Most treatments indicated that a tumour-elicited inflammatory response is indeed induced in HeLa cells and that the significant activation of nuclear factor kappa B (NF-κB) favoured the production of nitric oxide (NO) over cyclo-oxygenase 2 (COX-2). However, treatments with A. nemorosa, BC-7 and A. afra at their IC10 showed the potential of inhibiting this response. ROS levels were increased by most treatments and support the idea of ROS-mediated apoptosis. The third objective was to investigate combination treatments of these extracts and compounds for their potential synergistic cytotoxic activity and thus formulating the combinations as potential anti-cancer agents. Thirty combination mixtures were prepared using the IC50 values of each extract or compound at ratios of 1:3, 1:2, 1:1, 2:1 and 3:1, respectively. The cytotoxic/anti-proliferative activity of each mixture was determined by the bisBenzamide H 33342 trihydrochloride/propidium iodide (Hoechst 33342/PI) dual staining method on HeLa cervical cancer cells. The combination index (CI) values, at inhibition of 50% of HeLa cell growth, for each combination mixture, were determined by means of the Chou and Talalay method. The combined effect can then be indicated as CI < 1, synergism; CI = 1, additive effect or CI > 1, antagonism, respectively. Most combination treatments showed to have an antagonistic effect except for cisplatin:BC-7 (1:3, 1:1, 2:1, 3:1) and cisplatin:A. afra (1:3, 1:2, 1:1, 3:1) combinations that showed synergism. The 1:2 ratio of cisplatin:BC-7 and the 2:1 ratio of cisplatin:A. afra were additive. CI values were also calculated at inhibition of 10, 25 and 75% of HeLa cell growth, for each combination mixture. Antagonistic effects were frequently observed at lower effect levels such as at 10 and 25% inhibition of growth. However, this was not seen for the cisplatin:BC-7 combinations as all the ratios indicated synergism. Some of these ratios, such as the 1:3 and 1:2, even led to a greater degree of synergism being obtained, with noticeable antagonistic effects seen at 50 and 75% inhibition of growth. The current finding is that BC-7 and A. afra could lower the dose of cisplatin in combination to achieve a similar anti-cancer efficacy compared to the higher cisplatin dose when used alone. The lower dosage in combination could result in reduced drug resistance as well as limit the toxicity on normal cells associated with cisplatin treatment. In conclusion, this study shows, for the first time, that A. nemorosa has the potential to induce apoptosis and also has some anti- and pro-inflammatory activity in HeLa cancer cells. This study also enhanced the knowledge of the mechanism of apoptosis induction of BC-7, in a more detailed manner, as well as investigated its inflammatory effects for the first time. Results obtained for A. afra correlated nicely to previously reported studies and confirmed that the methods used in this study, although different, leads to the same conclusions. Combination treatments also indicated, for the first time, that BC-7 and A. afra have the ability to function in a synergic manner with cisplatin and proves that, although extensive research may have been done on a plant or compound, more can be discovered. This new information can lead to identification of new compounds in the plants and the integration of signalling pathways that can be targeted for treatment of cancer.
- Full Text:
- Date Issued: 2019
- Authors: Swanepoel, Bresler
- Date: 2019
- Subjects: Pharmaceutical chemistry , Cancer -- Research , Biomedical materials
- Language: English
- Type: Thesis , Masters , MSc
- Identifier: http://hdl.handle.net/10948/43957 , vital:37087
- Description: In the last two decades, anti-cancer therapy has grown considerably with the help of both natural and synthetic anti-cancer compounds but, the search for new and improved cancer treatment remains an ongoing and important issue. Some anti-cancer compounds such as cisplatin are limited by their toxicity in normal tissues and the development of drug resistance. Therefore, in order to address drug resistance and side-effects of anti-cancer agents, recent research has been focusing on finding novel combinations of anti-cancer agents that have non-overlapping mechanisms of action. The first objective of this study was to determine the mechanism of action of Anemone nemorosa, Artemisia afra, N-[[3-(4-bromophenyl)-1H-pyrazol-5-yl]-carbamothioyl]-4-chloro-benzamide (BC-7) and N-benzoyl-N’-(3-(4-bromophenyl)-1H-pyrazol-5-yl)-thiourea (BT-7) through cell cycle arrest, phosphatidylserine translocation (PS), caspase activation and mitochondrial membrane depolarization. This study has shown that A. nemorosa, BC-7 and A. afra are capable of inducing cell death within three cancer cell lines namely HeLa, MeWo and HepG2, at varying degrees. HeLa cells were the most susceptible to treatment with A. nemorosa and BC-7 with IC50 values of 20.33 ± 2.480 μg/ml and 65.58 ± 8.400 μM (28.58 ± 3.660 μg/ml), respectively. A. afra was the most active against HepG2 cells with an IC50 value of 37.55 μg/ml. BT-7 was not cytotoxic against any of the cancer cell lines. The effects on HeLa cells and their progression through the cell cycle indicated that cells were arrested in the early M phase for all treatments. The induction of apoptosis was confirmed by an increase in PS translocation and activation of caspase 3 and 8 as well as a decrease in the mitochondrial membrane potential. It was deduced that A. nemorosa, A. afra and BC-7 induce caspase-dependent apoptosis in a mitochondrial dependent manner. The second objective of this study was to investigate the potential of A. nemorosa, A. afra and BC-7 to target various mediators involved in the inflammatory response as an alternative method in which cell death may be induced. Most treatments indicated that a tumour-elicited inflammatory response is indeed induced in HeLa cells and that the significant activation of nuclear factor kappa B (NF-κB) favoured the production of nitric oxide (NO) over cyclo-oxygenase 2 (COX-2). However, treatments with A. nemorosa, BC-7 and A. afra at their IC10 showed the potential of inhibiting this response. ROS levels were increased by most treatments and support the idea of ROS-mediated apoptosis. The third objective was to investigate combination treatments of these extracts and compounds for their potential synergistic cytotoxic activity and thus formulating the combinations as potential anti-cancer agents. Thirty combination mixtures were prepared using the IC50 values of each extract or compound at ratios of 1:3, 1:2, 1:1, 2:1 and 3:1, respectively. The cytotoxic/anti-proliferative activity of each mixture was determined by the bisBenzamide H 33342 trihydrochloride/propidium iodide (Hoechst 33342/PI) dual staining method on HeLa cervical cancer cells. The combination index (CI) values, at inhibition of 50% of HeLa cell growth, for each combination mixture, were determined by means of the Chou and Talalay method. The combined effect can then be indicated as CI < 1, synergism; CI = 1, additive effect or CI > 1, antagonism, respectively. Most combination treatments showed to have an antagonistic effect except for cisplatin:BC-7 (1:3, 1:1, 2:1, 3:1) and cisplatin:A. afra (1:3, 1:2, 1:1, 3:1) combinations that showed synergism. The 1:2 ratio of cisplatin:BC-7 and the 2:1 ratio of cisplatin:A. afra were additive. CI values were also calculated at inhibition of 10, 25 and 75% of HeLa cell growth, for each combination mixture. Antagonistic effects were frequently observed at lower effect levels such as at 10 and 25% inhibition of growth. However, this was not seen for the cisplatin:BC-7 combinations as all the ratios indicated synergism. Some of these ratios, such as the 1:3 and 1:2, even led to a greater degree of synergism being obtained, with noticeable antagonistic effects seen at 50 and 75% inhibition of growth. The current finding is that BC-7 and A. afra could lower the dose of cisplatin in combination to achieve a similar anti-cancer efficacy compared to the higher cisplatin dose when used alone. The lower dosage in combination could result in reduced drug resistance as well as limit the toxicity on normal cells associated with cisplatin treatment. In conclusion, this study shows, for the first time, that A. nemorosa has the potential to induce apoptosis and also has some anti- and pro-inflammatory activity in HeLa cancer cells. This study also enhanced the knowledge of the mechanism of apoptosis induction of BC-7, in a more detailed manner, as well as investigated its inflammatory effects for the first time. Results obtained for A. afra correlated nicely to previously reported studies and confirmed that the methods used in this study, although different, leads to the same conclusions. Combination treatments also indicated, for the first time, that BC-7 and A. afra have the ability to function in a synergic manner with cisplatin and proves that, although extensive research may have been done on a plant or compound, more can be discovered. This new information can lead to identification of new compounds in the plants and the integration of signalling pathways that can be targeted for treatment of cancer.
- Full Text:
- Date Issued: 2019
The anti-proliferative activity of drimia altissima and a novel isolated flavonoid glycoside against hela cervical cancer cells
- Authors: Nyambe, Mutenta Nsokolo
- Date: 2019
- Subjects: Cancer -- Research , Cervix uteri -- Cancer , Cervix uteri -- Cancer -- Diagnosis -- Developing countries
- Language: English
- Type: Thesis , Doctoral , DPhil
- Identifier: http://hdl.handle.net/10948/42770 , vital:36690
- Description: Cancer is one of the leading causes of mortality worldwide. About 44% of all cancer morbidity and 53% of all cancer mortality occur in countries with a low to medium Human Development Index (HDI). Thus, cancer is rapidly emerging as a serious threat to public health in Africa and most especially, sub-Saharan Africa. The International Agency for Research on Cancer (IARC) projects that there will be 1.28 million new cancer cases and 970 000 cancer deaths in Africa by the year 2030 owing to the increase in economic development associated lifestyles. The dominant types of cancer in Africa are those related to infectious diseases such as Kaposi’s sarcoma and cervical, hepatic and urinary bladder carcinomas. The main challenge to cancer treatment in Africa is the unavailability of efficacious anticancer drugs. This is because most developing countries can only afford to procure the most basic anticancer drugs, which are also frequently unavailable due to intermittent supplies. This results in patients progressing to more advanced cancer states. One way of combating this African problem is to focus on research that aims at discovering efficacious and cost effective cancer therapies from available natural resources within the African continent. This study investigated the potential anti-proliferative activity (against HeLa cervical cancer cells) of four plants (Adansonia digitata, Ceiba pentandra, Maytenus senegalensis and Drimia altissima) commonly used in the African traditional treatment of malignancies. After in vitro bio-assay screening using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, M. senegalensis root extract (MS-R) and D. altissima bulb extract (DA-B) showed anti-proliferative activity against HeLa cervical cancer cells with IC50 values of 25 μg/mL and 1.1 μg/mL respectively. By possessing the strongest anti-proliferative activity among the tested extracts, D. altissima was selected for further studies. Liquid-liquid partitioning of the Drimia altissima bulb extract with n-hexane, ethyl acetate, and n-butanol, yielded partitions 79a – d, with the n-butanol fraction, 79d, exhibiting the strongest cytotoxic activity (IC50 = 0.497 μg/mL). Through High Content Analysis (HCA) screening, fraction 79d was found to induce marked early mitotic cell cycle arrest. Fractionation of 79d using Diaion® HP-20 open column chromatography and a stepwise gradient of reducing polarity (water-methanol-ethanol-ethyl acetate) yielded cytotoxic fractions 82b, 82c, 82d and 82e, all with significant anti-proliferative activities at the tested concentrations of 0.1, 1.0 and 10 μg/mL. Bio-assay guided fractionation of 82c (the most effective fraction at the lowest tested concentration of 0.1 μg/mL) using Sephadex® LH-20 open column chromatography and 50% MeOH led to the isolation of compound 3.17. After structural elucidation using 1D and 2D Nuclear Magnetic Resonance spectroscopy (NMR), High resolution Mass spectrometry (HRMS), Fourier-Transform Infrared spectroscopy (FT-IR), ultraviolet spectroscopy (UV) and Circular Dichroism (CD), compound 3.17 was identified as a novel C-glucosylflavonoid-O-glucoside, 6-C-[-apio-α-D-furanosyl-(1→6)-β-glucopyranosyl]-4′, 5, 7-trihydroxyflavone (Altissimin, 3.17). Compound 3.17 exhibited a dose dependant anti-proliferative activity with an IC50 of 2.44 μM. The mechanism of action for compound 3.17 was investigated through cell cycle arrest, phosphatidylserine translocation (PS), caspase activation and mitochondrial membrane depolarization. The mechanism of cell death elicited by compound 3.17 in HeLa cells was found to involve the induction of M phase cell cycle arrest with consequent activation of apoptotic cell death which was evident from annexin V staining, mitochondrial membrane potential (ΔΨm) collapse and the activation of caspases -8 and -3. In silico computational techniques were employed to virtually determine potential biological targets of compound 3.17. Target fishing using the Similarity Ensemble Approach (SEA) target prediction gave human aldose reductase (hAR, AKR1B1) the highest ranking with a p value of 2.85 x 10-24, a max Tc of 0.35 and a Z-score of 41.8217. Using AutoDock4 and the AutoDock tools suite (ADT), molecular docking of compound 3.17 in the hAR binding pocket was successfully achieved with a lower ΔG free energy binding (-9.4 kcal/mol) than that of positive control ligand 393 (-8.7 kcal/mol). In conclusion, this study identified the genus Drimia and particularly D. altissima as a potential source for novel cytotoxic compounds. The discovery of altissimin (3.17), the first flavonoid glycoside to be isolate from D. altissima, enquires into the possible existence of similar compounds within the species. In addition to the observed in vitro cytotoxic activity against HeLa cells, the potential of altissimin (3.17) as a hAR enzyme inhibitor opens up the possibility of its use as an adjunct to increase cancer cell sensitivity to chemotherapy. Thus, altissimin (3.17) shows promise as a potential anticancer agent.
- Full Text:
- Date Issued: 2019
- Authors: Nyambe, Mutenta Nsokolo
- Date: 2019
- Subjects: Cancer -- Research , Cervix uteri -- Cancer , Cervix uteri -- Cancer -- Diagnosis -- Developing countries
- Language: English
- Type: Thesis , Doctoral , DPhil
- Identifier: http://hdl.handle.net/10948/42770 , vital:36690
- Description: Cancer is one of the leading causes of mortality worldwide. About 44% of all cancer morbidity and 53% of all cancer mortality occur in countries with a low to medium Human Development Index (HDI). Thus, cancer is rapidly emerging as a serious threat to public health in Africa and most especially, sub-Saharan Africa. The International Agency for Research on Cancer (IARC) projects that there will be 1.28 million new cancer cases and 970 000 cancer deaths in Africa by the year 2030 owing to the increase in economic development associated lifestyles. The dominant types of cancer in Africa are those related to infectious diseases such as Kaposi’s sarcoma and cervical, hepatic and urinary bladder carcinomas. The main challenge to cancer treatment in Africa is the unavailability of efficacious anticancer drugs. This is because most developing countries can only afford to procure the most basic anticancer drugs, which are also frequently unavailable due to intermittent supplies. This results in patients progressing to more advanced cancer states. One way of combating this African problem is to focus on research that aims at discovering efficacious and cost effective cancer therapies from available natural resources within the African continent. This study investigated the potential anti-proliferative activity (against HeLa cervical cancer cells) of four plants (Adansonia digitata, Ceiba pentandra, Maytenus senegalensis and Drimia altissima) commonly used in the African traditional treatment of malignancies. After in vitro bio-assay screening using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, M. senegalensis root extract (MS-R) and D. altissima bulb extract (DA-B) showed anti-proliferative activity against HeLa cervical cancer cells with IC50 values of 25 μg/mL and 1.1 μg/mL respectively. By possessing the strongest anti-proliferative activity among the tested extracts, D. altissima was selected for further studies. Liquid-liquid partitioning of the Drimia altissima bulb extract with n-hexane, ethyl acetate, and n-butanol, yielded partitions 79a – d, with the n-butanol fraction, 79d, exhibiting the strongest cytotoxic activity (IC50 = 0.497 μg/mL). Through High Content Analysis (HCA) screening, fraction 79d was found to induce marked early mitotic cell cycle arrest. Fractionation of 79d using Diaion® HP-20 open column chromatography and a stepwise gradient of reducing polarity (water-methanol-ethanol-ethyl acetate) yielded cytotoxic fractions 82b, 82c, 82d and 82e, all with significant anti-proliferative activities at the tested concentrations of 0.1, 1.0 and 10 μg/mL. Bio-assay guided fractionation of 82c (the most effective fraction at the lowest tested concentration of 0.1 μg/mL) using Sephadex® LH-20 open column chromatography and 50% MeOH led to the isolation of compound 3.17. After structural elucidation using 1D and 2D Nuclear Magnetic Resonance spectroscopy (NMR), High resolution Mass spectrometry (HRMS), Fourier-Transform Infrared spectroscopy (FT-IR), ultraviolet spectroscopy (UV) and Circular Dichroism (CD), compound 3.17 was identified as a novel C-glucosylflavonoid-O-glucoside, 6-C-[-apio-α-D-furanosyl-(1→6)-β-glucopyranosyl]-4′, 5, 7-trihydroxyflavone (Altissimin, 3.17). Compound 3.17 exhibited a dose dependant anti-proliferative activity with an IC50 of 2.44 μM. The mechanism of action for compound 3.17 was investigated through cell cycle arrest, phosphatidylserine translocation (PS), caspase activation and mitochondrial membrane depolarization. The mechanism of cell death elicited by compound 3.17 in HeLa cells was found to involve the induction of M phase cell cycle arrest with consequent activation of apoptotic cell death which was evident from annexin V staining, mitochondrial membrane potential (ΔΨm) collapse and the activation of caspases -8 and -3. In silico computational techniques were employed to virtually determine potential biological targets of compound 3.17. Target fishing using the Similarity Ensemble Approach (SEA) target prediction gave human aldose reductase (hAR, AKR1B1) the highest ranking with a p value of 2.85 x 10-24, a max Tc of 0.35 and a Z-score of 41.8217. Using AutoDock4 and the AutoDock tools suite (ADT), molecular docking of compound 3.17 in the hAR binding pocket was successfully achieved with a lower ΔG free energy binding (-9.4 kcal/mol) than that of positive control ligand 393 (-8.7 kcal/mol). In conclusion, this study identified the genus Drimia and particularly D. altissima as a potential source for novel cytotoxic compounds. The discovery of altissimin (3.17), the first flavonoid glycoside to be isolate from D. altissima, enquires into the possible existence of similar compounds within the species. In addition to the observed in vitro cytotoxic activity against HeLa cells, the potential of altissimin (3.17) as a hAR enzyme inhibitor opens up the possibility of its use as an adjunct to increase cancer cell sensitivity to chemotherapy. Thus, altissimin (3.17) shows promise as a potential anticancer agent.
- Full Text:
- Date Issued: 2019
The role of cancer procoagulant on the MTOR pathway
- Authors: Chiuswa, Chengetanai
- Date: 2016
- Subjects: Cancer -- Research , Neovascularization , Biochemistry , Blood coagulation factors -- Biotechnology
- Language: English
- Type: Thesis , Masters , MSc
- Identifier: http://hdl.handle.net/10948/7303 , vital:21316
- Description: Cancer procoagulant (CP) is a cysteine protease found in tumour cells and amnion chorion membranes. The main function of CP is not yet known, but it has potential roles in tumour growth and metastasis. Initially, CP was believed to increase coagulation in cancer patients; however, research has shown that increase in CP concentration does not correlate with an increase in coagulation. The location of CP in amnion chorion membranes and tumour cells only led to the hypothesis that CP might be involved in inducing blood vessel and or lymph vessel formation. CP was shown to induce lymphangiogenesis (lymph vessel formation) in human telomerase reverse transcriptase-human dermal endothelial cells (hTERT-HDLEC) (Tshaka, 2011). CP-induced tube formation was inhibited by rapamycin; indicating that CP may be signalling via the mammalian target of rapamycin (mTOR) pathway. The aim of this study was to investigate the effect of CP on the mTOR signalling pathway using human umbilical endothelial vein cells (HUVECs) as a model. CP was isolated from amnion chorion membranes and purified using two anion exchange chromatography steps. Purified CP (2 μg/ml) was used to induce tube formation in endothelial cells (HUVECs) seeded on growth factor reduced (GFR) Matrigel. In addition, the 2 μg/ml CP was used to treat cultured HUVECs. Sodium dodecyl sulphate polyacrylamide electrophoresis (SDS-PAGE) and western blotting were used to determine phosphorylation levels of protein kinase B (Akt) and ribosomal protein S6 kinase (S6K). CP was successfully isolated and purified using anion exchange chromatography. The effect of CP on tube formation was not significant relative to the control in the HUVEC cell line. The role of CP on Akt and S6K phosphorylation still needs to be verified by using sensitive methods of quantification such as enhanced chemiluminescence (ECL) and enzyme linked immunosorbent assay (ELISA). The levels of CP activity were shown to be higher in early tumour growth than in advanced cancer suggesting that certain physiological factors could be increasing CP activity during early tumour growth. This study investigated the effect of cobalt chloride on CP activity in breast cancer cell lines. Cobalt chloride reduced CP activity in MCF-7 and promoted CP activity in MDA-MB-231.
- Full Text:
- Date Issued: 2016
- Authors: Chiuswa, Chengetanai
- Date: 2016
- Subjects: Cancer -- Research , Neovascularization , Biochemistry , Blood coagulation factors -- Biotechnology
- Language: English
- Type: Thesis , Masters , MSc
- Identifier: http://hdl.handle.net/10948/7303 , vital:21316
- Description: Cancer procoagulant (CP) is a cysteine protease found in tumour cells and amnion chorion membranes. The main function of CP is not yet known, but it has potential roles in tumour growth and metastasis. Initially, CP was believed to increase coagulation in cancer patients; however, research has shown that increase in CP concentration does not correlate with an increase in coagulation. The location of CP in amnion chorion membranes and tumour cells only led to the hypothesis that CP might be involved in inducing blood vessel and or lymph vessel formation. CP was shown to induce lymphangiogenesis (lymph vessel formation) in human telomerase reverse transcriptase-human dermal endothelial cells (hTERT-HDLEC) (Tshaka, 2011). CP-induced tube formation was inhibited by rapamycin; indicating that CP may be signalling via the mammalian target of rapamycin (mTOR) pathway. The aim of this study was to investigate the effect of CP on the mTOR signalling pathway using human umbilical endothelial vein cells (HUVECs) as a model. CP was isolated from amnion chorion membranes and purified using two anion exchange chromatography steps. Purified CP (2 μg/ml) was used to induce tube formation in endothelial cells (HUVECs) seeded on growth factor reduced (GFR) Matrigel. In addition, the 2 μg/ml CP was used to treat cultured HUVECs. Sodium dodecyl sulphate polyacrylamide electrophoresis (SDS-PAGE) and western blotting were used to determine phosphorylation levels of protein kinase B (Akt) and ribosomal protein S6 kinase (S6K). CP was successfully isolated and purified using anion exchange chromatography. The effect of CP on tube formation was not significant relative to the control in the HUVEC cell line. The role of CP on Akt and S6K phosphorylation still needs to be verified by using sensitive methods of quantification such as enhanced chemiluminescence (ECL) and enzyme linked immunosorbent assay (ELISA). The levels of CP activity were shown to be higher in early tumour growth than in advanced cancer suggesting that certain physiological factors could be increasing CP activity during early tumour growth. This study investigated the effect of cobalt chloride on CP activity in breast cancer cell lines. Cobalt chloride reduced CP activity in MCF-7 and promoted CP activity in MDA-MB-231.
- Full Text:
- Date Issued: 2016
Identification of membrane biomakers for colorectal cancer using an in-solico and molecular approach
- Authors: Van Vuuren, Larry Peter
- Date: 2014
- Subjects: Cancer -- Research , Colon (Anatomy) -- Cancer , Rectum -- Cancer
- Language: English
- Type: Thesis , Masters , MSc
- Identifier: http://hdl.handle.net/10948/47970 , vital:40457
- Description: The aim of this study was to identify membrane biomarkers for colorectal cancer using an insilico and molecular approach. Colorectal cancer (CRC) globally accounts for more than half a million deaths. In South Africa alone, approximately one in 97 men is at risk of getting CRC; and for women, it is one in 162. Novel and non-invasive diagnostic tools, such as biomarkers, are needed for early CRC detection. In order to reduce the fatality rate in this disease, Biomarkers are used as indicators of a biological state; and they are measurable in biological media. They can be used to distinguish between a diseased state and a normal state, thus aiding diagnostics, response to specific therapies, and screening for an early diagnosis. A gene list of potential CRC biomarkers was generated by mining two gene databases, namely: Oncomine and Gene Expression Atlas. A total of 44 candidate genes were identified, based on their location on the cell surface, using the Database for Annotation, Visualisation and Integrated Discovery. These 44 genes were then subjected to an in-depth literature mining. The literature search parameters in PubMed, PubMed Central, Google Scholar and Science direct revealed publications showing that 23 genes were validated, while 21 genes were not validated. Nineteen genes were selected for gene validation in human colorectal cancer and healthy tissue of twelve patients. Total RNA was extracted from 12 colorectal cancer and 12 healthy tissue samples. The RNA was then quantified and reverse-transcribed into cDNA for gene expression analysis. The qPCR running conditions were optimized, by running a melting curve, in order to determine the optimum annealing temperatures. Primarily melt curves were run for nineteen of these twenty-one genes. Melt-curve analysis showed that nine genes were poor candidates for further validation studies; and therefore, only ten genes, namely: AGTRAP, ANKRD46, BACE2, CFB, CIAO1, NOMO3, PTDSS1, SLC5A6, TNFRSF12A and ZDHHC9 were validated by qPCR in human resected colorectal carcinoma and the normal tissues of twelve patients. The qPCR results showed that ZDHHC9 and the SLC5A6 genes were the only two statistically significant ones; and they were found to be down-regulated in human colorectal cancer vs healthy tissue samples.
- Full Text:
- Date Issued: 2014
Identification of membrane biomakers for colorectal cancer using an in-solico and molecular approach
- Authors: Van Vuuren, Larry Peter
- Date: 2014
- Subjects: Cancer -- Research , Colon (Anatomy) -- Cancer , Rectum -- Cancer
- Language: English
- Type: Thesis , Masters , MSc
- Identifier: http://hdl.handle.net/10948/47970 , vital:40457
- Description: The aim of this study was to identify membrane biomarkers for colorectal cancer using an insilico and molecular approach. Colorectal cancer (CRC) globally accounts for more than half a million deaths. In South Africa alone, approximately one in 97 men is at risk of getting CRC; and for women, it is one in 162. Novel and non-invasive diagnostic tools, such as biomarkers, are needed for early CRC detection. In order to reduce the fatality rate in this disease, Biomarkers are used as indicators of a biological state; and they are measurable in biological media. They can be used to distinguish between a diseased state and a normal state, thus aiding diagnostics, response to specific therapies, and screening for an early diagnosis. A gene list of potential CRC biomarkers was generated by mining two gene databases, namely: Oncomine and Gene Expression Atlas. A total of 44 candidate genes were identified, based on their location on the cell surface, using the Database for Annotation, Visualisation and Integrated Discovery. These 44 genes were then subjected to an in-depth literature mining. The literature search parameters in PubMed, PubMed Central, Google Scholar and Science direct revealed publications showing that 23 genes were validated, while 21 genes were not validated. Nineteen genes were selected for gene validation in human colorectal cancer and healthy tissue of twelve patients. Total RNA was extracted from 12 colorectal cancer and 12 healthy tissue samples. The RNA was then quantified and reverse-transcribed into cDNA for gene expression analysis. The qPCR running conditions were optimized, by running a melting curve, in order to determine the optimum annealing temperatures. Primarily melt curves were run for nineteen of these twenty-one genes. Melt-curve analysis showed that nine genes were poor candidates for further validation studies; and therefore, only ten genes, namely: AGTRAP, ANKRD46, BACE2, CFB, CIAO1, NOMO3, PTDSS1, SLC5A6, TNFRSF12A and ZDHHC9 were validated by qPCR in human resected colorectal carcinoma and the normal tissues of twelve patients. The qPCR results showed that ZDHHC9 and the SLC5A6 genes were the only two statistically significant ones; and they were found to be down-regulated in human colorectal cancer vs healthy tissue samples.
- Full Text:
- Date Issued: 2014
The development of novel cancer targeting agents
- Authors: Knoetze, Steyn
- Date: 2011
- Subjects: Cancer -- Research , Cancer -- Treatment
- Language: English
- Type: Thesis , Doctoral , DPhil
- Identifier: vital:10397 , http://hdl.handle.net/10948/d1010636 , Cancer -- Research , Cancer -- Treatment
- Description: The search for the cure for cancer is currently a multi-billion dollar industry and the search for the elusive “magic bullet”, i.e. the perfect cancer drug that would interact therapeutically with cancerous tissues while having a minimal effect on healthy cells, is the topic of many research studies in the world today. A large number of novel drugs or drug complexes and conjugates are being synthesized and subjected to rigorous evaluation in the race to find the perfect cure. ECDG (Ethylene diCysteine DeoxyGlucose) seems to have promising cancer targeting ability. Even though this compound has been described in a few publications, we could not find any reference to the current use of ECDG in oncology clinics, either as a therapeutic agent, or as a diagnostic tool for imaging purposes. It was also not possible to purchase pure ECDG anywhere in the world. This prompted us to further investigate ECDG as a possible candidate for cancer targeting research, either as an imaging agent for cancer diagnosis or complexed with an anti-cancer agent for therapeutic purposes. Detailed investigations done in our laboratory can be divided into the following categories: - Development of a synthetic method for ECDG on a multigram scale ; - Purification of prepared ECDG not using the described dialysis method that only allows the purification of small quantities of ECDG (mg scale) ; Detailed investigation of the chemistry involved in the preparation of pure ECDG and its metal complexes ; - Investigation of the stability of ECDG and its metal complexes that is essential data required for any pharmaceutical agent ; - Preparation of ECDG complexes for use as a diagnostic tool, i.e. complexation with 99mTc ; Investigation of the bio distribution of ECDG-ReO complexes ; - Preparation of an ECDG kit as a diagnostic tool for use in oncology clinics. The development of novel aromatic ligands having similar characteristics compared to ECDG, containing an N2S2 chromophore as donor atoms, to further investigate their targeting capabilities, have also been investigated. All intermediates and final compounds were characterized mainly by ESI MS, in some cases IR and NMR whenever available. Successful preparation and purification of ECDG ands its metal complexes was achieved and extensively characterized and evaluated. Efforts directed towards the development of ECDG at NECSA, South Africa, were also rewarded with significant success. Furthermore, significant development regarding the synthesis of two novel compounds with ECDG-like characteristics was also completed.
- Full Text:
- Date Issued: 2011
- Authors: Knoetze, Steyn
- Date: 2011
- Subjects: Cancer -- Research , Cancer -- Treatment
- Language: English
- Type: Thesis , Doctoral , DPhil
- Identifier: vital:10397 , http://hdl.handle.net/10948/d1010636 , Cancer -- Research , Cancer -- Treatment
- Description: The search for the cure for cancer is currently a multi-billion dollar industry and the search for the elusive “magic bullet”, i.e. the perfect cancer drug that would interact therapeutically with cancerous tissues while having a minimal effect on healthy cells, is the topic of many research studies in the world today. A large number of novel drugs or drug complexes and conjugates are being synthesized and subjected to rigorous evaluation in the race to find the perfect cure. ECDG (Ethylene diCysteine DeoxyGlucose) seems to have promising cancer targeting ability. Even though this compound has been described in a few publications, we could not find any reference to the current use of ECDG in oncology clinics, either as a therapeutic agent, or as a diagnostic tool for imaging purposes. It was also not possible to purchase pure ECDG anywhere in the world. This prompted us to further investigate ECDG as a possible candidate for cancer targeting research, either as an imaging agent for cancer diagnosis or complexed with an anti-cancer agent for therapeutic purposes. Detailed investigations done in our laboratory can be divided into the following categories: - Development of a synthetic method for ECDG on a multigram scale ; - Purification of prepared ECDG not using the described dialysis method that only allows the purification of small quantities of ECDG (mg scale) ; Detailed investigation of the chemistry involved in the preparation of pure ECDG and its metal complexes ; - Investigation of the stability of ECDG and its metal complexes that is essential data required for any pharmaceutical agent ; - Preparation of ECDG complexes for use as a diagnostic tool, i.e. complexation with 99mTc ; Investigation of the bio distribution of ECDG-ReO complexes ; - Preparation of an ECDG kit as a diagnostic tool for use in oncology clinics. The development of novel aromatic ligands having similar characteristics compared to ECDG, containing an N2S2 chromophore as donor atoms, to further investigate their targeting capabilities, have also been investigated. All intermediates and final compounds were characterized mainly by ESI MS, in some cases IR and NMR whenever available. Successful preparation and purification of ECDG ands its metal complexes was achieved and extensively characterized and evaluated. Efforts directed towards the development of ECDG at NECSA, South Africa, were also rewarded with significant success. Furthermore, significant development regarding the synthesis of two novel compounds with ECDG-like characteristics was also completed.
- Full Text:
- Date Issued: 2011
Purification and characterization of fructosyltransferase for the synthesis of short-chain fructo-oligosaccharides and investigation into thier anti-carcinogenic properties
- Authors: Nemukula, Aluwani
- Date: 2009
- Subjects: Oligosaccharides , Polygalacturonase , Aspergillus , Fructose , Inulin , Cancer -- Prevention , Cancer -- Research , Carcinogens , High performance liquid chromatography
- Language: English
- Type: Thesis , Masters , MSc
- Identifier: vital:3927 , http://hdl.handle.net/10962/d1003986 , Oligosaccharides , Polygalacturonase , Aspergillus , Fructose , Inulin , Cancer -- Prevention , Cancer -- Research , Carcinogens , High performance liquid chromatography
- Description: There is a growing attention in the synthesis of fructo-oligosaccharides (FOS) due to their excellent bio-functional and health-promoting properties. The current production processes are limited to chemical hydrolysis reactions of plant extracts, which are often associated with several drawbacks. In this study, fructosyltransferase (FTase) and polygalacturonase (PGase) activities, present in a commercial enzyme preparation (Pectinex® Ultra SP-L) sourced from Aspergillus aculeatus, have been separated and fully purified by anion-exchange and sizeexclusion chromatography. The FTase possesses fructosyl transfer activity for FOS synthesis and the PGase has pectin hydrolytic activity. Fructosyltransferase is a single-band protein with a molecular weight of 85 kDa, whereas PGase is a distinct protein of 40 kDa. The temperature and pH optima of FTase were 60 ºC and 6.0, with a half-life of 8 h; while that for PGase were 40 ºC and 6.0, respectively. FTase was slightly inhibited in the presence of Ni²⁺, Mg²⁺ and urea; but PGase was more susceptible to divalent ions such as Ca²⁺, Mg²⁺ and Mn²⁺. The kinetic parameters (Km and Vmax) of FTase for the hydrolysis of β-(2→1) linkages from sucrose were 752.3 mM and 120.5 μmol.min⁻¹.mL⁻¹, respectively; whereas the same parameters for pectin hydrolysis by PGase were 13.0 mg.mL⁻¹ and 263 μmol.min-1.mL⁻¹, respectively. The purified FTase was able to transfer fructosyl residues from sucrose, synthesizing the corresponding chains of FOS. PGase was relatively stable at 40 ºC (t½ > 3 h), depolymerizing the pectin backbone while releasing the inulins from within the chicory roots. Analysis of various mixtures of FOS by mass spectrometry, HPLC and ¹H-NMR was undertaken. Results indicated that MS with electrospray ionization and ¹H-NMR are capable of providing relative quantitative data of the FOS present in the mixtures. The pharmaceutical effects of various sc-FOS (0.5%, v/v) and SCFA (0.3%, v/v) on certain bacterial enzymes (β-glucuronidase, urease and β-glucosidase) associated with the formation of carcinogens were also studied. These enzyme activities were not directly influenced by the sc-FOS, but were found to be remarkably decreased by SCFA, pointing toward the prebiotic effect of FOS in intestinal microflora modulation.
- Full Text:
- Date Issued: 2009
- Authors: Nemukula, Aluwani
- Date: 2009
- Subjects: Oligosaccharides , Polygalacturonase , Aspergillus , Fructose , Inulin , Cancer -- Prevention , Cancer -- Research , Carcinogens , High performance liquid chromatography
- Language: English
- Type: Thesis , Masters , MSc
- Identifier: vital:3927 , http://hdl.handle.net/10962/d1003986 , Oligosaccharides , Polygalacturonase , Aspergillus , Fructose , Inulin , Cancer -- Prevention , Cancer -- Research , Carcinogens , High performance liquid chromatography
- Description: There is a growing attention in the synthesis of fructo-oligosaccharides (FOS) due to their excellent bio-functional and health-promoting properties. The current production processes are limited to chemical hydrolysis reactions of plant extracts, which are often associated with several drawbacks. In this study, fructosyltransferase (FTase) and polygalacturonase (PGase) activities, present in a commercial enzyme preparation (Pectinex® Ultra SP-L) sourced from Aspergillus aculeatus, have been separated and fully purified by anion-exchange and sizeexclusion chromatography. The FTase possesses fructosyl transfer activity for FOS synthesis and the PGase has pectin hydrolytic activity. Fructosyltransferase is a single-band protein with a molecular weight of 85 kDa, whereas PGase is a distinct protein of 40 kDa. The temperature and pH optima of FTase were 60 ºC and 6.0, with a half-life of 8 h; while that for PGase were 40 ºC and 6.0, respectively. FTase was slightly inhibited in the presence of Ni²⁺, Mg²⁺ and urea; but PGase was more susceptible to divalent ions such as Ca²⁺, Mg²⁺ and Mn²⁺. The kinetic parameters (Km and Vmax) of FTase for the hydrolysis of β-(2→1) linkages from sucrose were 752.3 mM and 120.5 μmol.min⁻¹.mL⁻¹, respectively; whereas the same parameters for pectin hydrolysis by PGase were 13.0 mg.mL⁻¹ and 263 μmol.min-1.mL⁻¹, respectively. The purified FTase was able to transfer fructosyl residues from sucrose, synthesizing the corresponding chains of FOS. PGase was relatively stable at 40 ºC (t½ > 3 h), depolymerizing the pectin backbone while releasing the inulins from within the chicory roots. Analysis of various mixtures of FOS by mass spectrometry, HPLC and ¹H-NMR was undertaken. Results indicated that MS with electrospray ionization and ¹H-NMR are capable of providing relative quantitative data of the FOS present in the mixtures. The pharmaceutical effects of various sc-FOS (0.5%, v/v) and SCFA (0.3%, v/v) on certain bacterial enzymes (β-glucuronidase, urease and β-glucosidase) associated with the formation of carcinogens were also studied. These enzyme activities were not directly influenced by the sc-FOS, but were found to be remarkably decreased by SCFA, pointing toward the prebiotic effect of FOS in intestinal microflora modulation.
- Full Text:
- Date Issued: 2009
Metabolic responses to in vitro zinc supplementation
- Authors: Steel, Helen Carolyn
- Date: 1994
- Subjects: Zinc in the body , Zinc -- Physiological effect , Cancer -- Research
- Language: English
- Type: Thesis , Masters , MSc
- Identifier: vital:4040 , http://hdl.handle.net/10962/d1004101 , Zinc in the body , Zinc -- Physiological effect , Cancer -- Research
- Description: The present study was carried out to determine the effects and possible mechanism of action of zinc supplementation on the in vitro growth of malignant murine melanoma (B16) and non-malignant monkey kidney (LLCMK) cells. Cell culture studies showed that zinc supplementation significantly inhibited B16 growth at all the concentrations studied (1, 3, 5 and lOμg/ml). Zinc was also found to inhibit the growth of the LLCMK cells, although to a lesser extent than the B16 cells. Possible evidence of mobilisation of the essential fatty acids from the membrane phospholipid stores was noted in both cell types. This effect was, however, greater in the B16 cells. Δ⁶-desaturase activity was found to be significantly lower in the B16 cells than in the LLCMK cells (p ≥ 0.05). Zinc supplementation resulted in an increase in the enzymes activity in the LLCMK cells and, at high concentrations, in the B16 cells. An estimation of elongase and Δ⁶-desaturase activity with zinc supplementation indicated that zinc had little or no effect on the activity of these enzymes. B16 cells were found to have higher levels of free radicals than the LLCMK cells. Zinc supplementation resulted in increased free radical formation in the B16 cells, while no effect was observed in the LLCMK cells. Lipid peroxidation increased in both cell types with increased zinc concentrations. The observed effect of zinc supplementation on cell growth may involve these elevated levels of lipid peroxides. CycIo-oxygenase activity was found to be greater in the B16 cells than the LLCMK cells. The activity of the enzyme increased with higher concentrations of zinc (lOμg/ml) in both cell types. Prostaglandin E, levels were found to be lower in the B16 cells compared to the LLCMK cells. The levels of prostaglandin E, in both cell types appeared to be dependent on the levels of the polyunsaturated fatty acid precursors to the prostaglandins. Zinc was found to inhibit the activity of the enzyme adenylate cyclase in both cell types. The cAMP levels in the LLCMK cells were also found to decrease with zinc supplementation. In the case of the B16 cells, cAMP levels increased at low concentrations of zinc despite a decrease in adenyl ate cyclase activity, suggesting a possible inhibition of cAMP phosphodiesterase activity at these concentrations of zinc. It is concluded that although zinc supplementation does have an effect on cell growth, this effect is not mediated through the activation of adenylate cyclase by the prostaglandins resulting in elevated levels of cAMP. A possible mechanism involving lipid peroxidation is proposed.
- Full Text:
- Date Issued: 1994
- Authors: Steel, Helen Carolyn
- Date: 1994
- Subjects: Zinc in the body , Zinc -- Physiological effect , Cancer -- Research
- Language: English
- Type: Thesis , Masters , MSc
- Identifier: vital:4040 , http://hdl.handle.net/10962/d1004101 , Zinc in the body , Zinc -- Physiological effect , Cancer -- Research
- Description: The present study was carried out to determine the effects and possible mechanism of action of zinc supplementation on the in vitro growth of malignant murine melanoma (B16) and non-malignant monkey kidney (LLCMK) cells. Cell culture studies showed that zinc supplementation significantly inhibited B16 growth at all the concentrations studied (1, 3, 5 and lOμg/ml). Zinc was also found to inhibit the growth of the LLCMK cells, although to a lesser extent than the B16 cells. Possible evidence of mobilisation of the essential fatty acids from the membrane phospholipid stores was noted in both cell types. This effect was, however, greater in the B16 cells. Δ⁶-desaturase activity was found to be significantly lower in the B16 cells than in the LLCMK cells (p ≥ 0.05). Zinc supplementation resulted in an increase in the enzymes activity in the LLCMK cells and, at high concentrations, in the B16 cells. An estimation of elongase and Δ⁶-desaturase activity with zinc supplementation indicated that zinc had little or no effect on the activity of these enzymes. B16 cells were found to have higher levels of free radicals than the LLCMK cells. Zinc supplementation resulted in increased free radical formation in the B16 cells, while no effect was observed in the LLCMK cells. Lipid peroxidation increased in both cell types with increased zinc concentrations. The observed effect of zinc supplementation on cell growth may involve these elevated levels of lipid peroxides. CycIo-oxygenase activity was found to be greater in the B16 cells than the LLCMK cells. The activity of the enzyme increased with higher concentrations of zinc (lOμg/ml) in both cell types. Prostaglandin E, levels were found to be lower in the B16 cells compared to the LLCMK cells. The levels of prostaglandin E, in both cell types appeared to be dependent on the levels of the polyunsaturated fatty acid precursors to the prostaglandins. Zinc was found to inhibit the activity of the enzyme adenylate cyclase in both cell types. The cAMP levels in the LLCMK cells were also found to decrease with zinc supplementation. In the case of the B16 cells, cAMP levels increased at low concentrations of zinc despite a decrease in adenyl ate cyclase activity, suggesting a possible inhibition of cAMP phosphodiesterase activity at these concentrations of zinc. It is concluded that although zinc supplementation does have an effect on cell growth, this effect is not mediated through the activation of adenylate cyclase by the prostaglandins resulting in elevated levels of cAMP. A possible mechanism involving lipid peroxidation is proposed.
- Full Text:
- Date Issued: 1994
Zinc inhibition of cell division : its relevance to cancer cells and possible mechanism of action
- Authors: Skeef, Noel Samuel
- Date: 1989
- Subjects: Cell division , Cancer cells -- Growth -- Regulation , Zinc in the body , Zinc -- Physiological effect , Cancer -- Research
- Language: English
- Type: Thesis , Doctoral , PhD
- Identifier: vital:4144 , http://hdl.handle.net/10962/d1016266
- Description: A description of two techniques used extensively in this study namely cell counting with a "cell counting plate" and argentation TLC for the separation of ω -6 -fatty acids is given. Zn supplementation into GM of two malignant (BL-6 and Hep- 350) and a non-malignant (LLC-MK) cell line/s resulted in an increased uptake of Zn by the cells and progressively suppressed proliferation of particularly the malignant cells. Zn chelation by EDTA suppressed in vitro proliferation of all 3 cell line, this effect being more pronounced in the malignant cells. A dietary Zn deficiency resulted in alopecia in mice and both a dietary Zn deficiency and Zn excess reduced growth of BL-6 tumours implanted subcutaneously in mice. Zn supplementation into GM progressively increased the uptake of [1-¹⁴C]-LA by BL-6 and LLC-MK cells but had a very slight though irregular effect on this parameter in the Hep- 350 cells. Zn supplementation also stimulated desaturase activity in the BL-6 cells. These results suggested that there are select cell lines whose Δ⁶-desaturase activity responds positively to Zn supplementation (e.g. the BL-6 cells). Delta-6-desaturase activity was also assayed in microsome preparations from different tissues. No enzyme activity was detected in the microsomes prepared from the BL-6 tumours. There was no significant effect with the addition of Zn or EDTA, on Δ⁶-desaturase activity of the regenerating liver microsomes. In the resting liver microsomes this enzyme activity was reduced only when EDTA and Zn were added together and when EDTA was added to the reaction medium as well as to the microsome preparations 2 hr before the enzyme activity assay was initiated. The results of these experiments suggested that the Δ⁶-desaturase enzyme in the microsome preparations may have had an adequate amount of Zn with further additions having no stimulatory effect on the enzyme. Two independent mechanisms of control of cell proliferation by low and high Zn are suggested to operate.
- Full Text:
- Date Issued: 1989
- Authors: Skeef, Noel Samuel
- Date: 1989
- Subjects: Cell division , Cancer cells -- Growth -- Regulation , Zinc in the body , Zinc -- Physiological effect , Cancer -- Research
- Language: English
- Type: Thesis , Doctoral , PhD
- Identifier: vital:4144 , http://hdl.handle.net/10962/d1016266
- Description: A description of two techniques used extensively in this study namely cell counting with a "cell counting plate" and argentation TLC for the separation of ω -6 -fatty acids is given. Zn supplementation into GM of two malignant (BL-6 and Hep- 350) and a non-malignant (LLC-MK) cell line/s resulted in an increased uptake of Zn by the cells and progressively suppressed proliferation of particularly the malignant cells. Zn chelation by EDTA suppressed in vitro proliferation of all 3 cell line, this effect being more pronounced in the malignant cells. A dietary Zn deficiency resulted in alopecia in mice and both a dietary Zn deficiency and Zn excess reduced growth of BL-6 tumours implanted subcutaneously in mice. Zn supplementation into GM progressively increased the uptake of [1-¹⁴C]-LA by BL-6 and LLC-MK cells but had a very slight though irregular effect on this parameter in the Hep- 350 cells. Zn supplementation also stimulated desaturase activity in the BL-6 cells. These results suggested that there are select cell lines whose Δ⁶-desaturase activity responds positively to Zn supplementation (e.g. the BL-6 cells). Delta-6-desaturase activity was also assayed in microsome preparations from different tissues. No enzyme activity was detected in the microsomes prepared from the BL-6 tumours. There was no significant effect with the addition of Zn or EDTA, on Δ⁶-desaturase activity of the regenerating liver microsomes. In the resting liver microsomes this enzyme activity was reduced only when EDTA and Zn were added together and when EDTA was added to the reaction medium as well as to the microsome preparations 2 hr before the enzyme activity assay was initiated. The results of these experiments suggested that the Δ⁶-desaturase enzyme in the microsome preparations may have had an adequate amount of Zn with further additions having no stimulatory effect on the enzyme. Two independent mechanisms of control of cell proliferation by low and high Zn are suggested to operate.
- Full Text:
- Date Issued: 1989
- «
- ‹
- 1
- ›
- »